•  Investment in purpose-built facilities supports ongoing recruitment and growth in new product development activities
• First phase of new facility doubles overall space capacity, with view to expand further as later stages of building complete

Cambridge, UK: Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Company’s growth. Doubling overall capacity, the laboratories enable the team’s accelerated expansion, and the development of new, innovative products.

The new facilities accommodate recent hires to Sphere Fluidics’ commercial and leadership team, as well as preparing for further recruitment by the end of the year. The first phase of building has opened 7,000 sq ft of space and has been purpose built with state-of-the-art equipment, including a demonstration lab to give customers the opportunity to see the Company’s single cell analysis and monoclonality assurance systems at work. The second phase, due to complete by the end of the 2023, will expand the Company’s footprint further to around 30,000 sq ft.

Granta Park is one of the UK’s leading life-science research parks and a world-renowned centre of excellence spanning over 120 acres of land. Custom designed and renovated by COEL, Sphere Fluidics’ new laboratories are in addition to offices at Babraham Research Campus, also in Cambridgeshire (UK). The Company also has an established network of international distributors in Japan, France, China, Switzerland, Germany, Austria, Benelux, Australia, Scandinavia, Korea and the USA.

Dr Frank F Craig, CEO, Sphere Fluidics, commented “We are on an exciting growth trajectory – this state-of-the-art site at Granta Park gives us another opportunity to attract new talent to our team, and continue our rapid expansion. With the first stage of building complete, we look forward to harnessing the space to encourage customer visits and sales and develop new products for our customers.”

Rob Treanor, Director of Operations, Sphere Fluidics, added “It is important that our scientific and commercial teams are provided with the very best environment to work, and with our new world-class facilities, we are proud to be able to offer this within one of the UK’s most prestigious science parks. We hope to have the entire UK workforce under one roof by the end of next year, as we continue to develop the business.”

For more information about Sphere Fluidics, please visit: https://spherefluidics.com/

For further information please contact:

Sphere Fluidics

Dr. Frank F. Craig

Email: [email protected]

Zyme Communications

Ellie Chandrasma

Email: [email protected]

About Sphere Fluidics www.spherefluidics.com

Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable leading edge research and accelerate biotherapeutic discovery and development.

The Company’s picodroplet incubation technology enables ultra-sensitive, rapid miniaturized assays of target protein secreted from tens of millions of individual cells.

Sphere Fluidics’ Cyto-Mine^® System integrates isolation, selective screening, sorting, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run.

Sphere Fluidics is located in Babraham Research Campus and Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors.

Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.